Clopidogrel Response Variability: Etiology and Clinical Relevance

[1]  P. Kolh,et al.  [2014 ESC/EACTS Guidelines on myocardial revascularization]. , 2014, Kardiologia polska.

[2]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  Masafumi Ueno,et al.  Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. , 2014, Journal of the American College of Cardiology.

[4]  J. Mega,et al.  Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. , 2014, Journal of the American College of Cardiology.

[5]  M. Posch,et al.  Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. , 2014, Journal of the American College of Cardiology.

[6]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[7]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[8]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[9]  T. Nolin,et al.  The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. , 2013, Journal of the American College of Cardiology.

[10]  R. Koppensteiner,et al.  Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  I. Barbash,et al.  Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention. , 2013, American heart journal.

[12]  Samin K. Sharma,et al.  Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity , 2013, Thrombosis and Haemostasis.

[13]  S. Qiao,et al.  Effect of the CYP2C19*2 and *3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention , 2013, European Journal of Clinical Pharmacology.

[14]  T. Luo,et al.  Pharmacodynamic Impacts of Proton Pump Inhibitors on the Efficacy of Clopidogrel In Vivo—A Systematic Review , 2013, Clinical cardiology.

[15]  P. Morange,et al.  CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. , 2012, JACC. Cardiovascular interventions.

[16]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[17]  G. Lemesle,et al.  Relationship between post‐treatment platelet reactivity and ischemic and bleeding events at 1‐year follow‐up in patients receiving prasugrel , 2012, Journal of thrombosis and haemostasis : JTH.

[18]  P. Gurbel,et al.  Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. , 2012, European heart journal.

[19]  D. Kim,et al.  Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. , 2012, The American journal of cardiology.

[20]  Y. Daali,et al.  Influence of the paraoxonase‐1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta‐analysis , 2012, Journal of thrombosis and haemostasis : JTH.

[21]  G. Montalescot,et al.  High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. , 2012, European heart journal.

[22]  P. Barragan,et al.  Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction , 2012, Thrombosis and Haemostasis.

[23]  G. Parodi,et al.  Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. , 2012, The American journal of cardiology.

[24]  M. Price,et al.  Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. , 2011, Journal of the American College of Cardiology.

[25]  C. Hirschhäuser,et al.  Paraoxonase-1 is a major determinant of clopidogrel efficacy , 2011, Nature Medicine.

[26]  M. Pansieri,et al.  High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. , 2011, Journal of the American College of Cardiology.

[27]  A. Kastrati,et al.  No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. , 2011, European heart journal.

[28]  E. Antman,et al.  Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel , 2011, Thrombosis and Haemostasis.

[29]  V. Pasceri,et al.  Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). , 2011, The American journal of cardiology.

[30]  P. Weeke,et al.  Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. , 2011, Journal of the American College of Cardiology.

[31]  Deepak L. Bhatt,et al.  Clopidogrel with or without omeprazole in coronary artery disease. , 2010, The New England journal of medicine.

[32]  E. Antman,et al.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. , 2010, JAMA.

[33]  B. J. Barratt,et al.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial , 2010, The Lancet.

[34]  E. Antman,et al.  Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis , 2010, The Lancet.

[35]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[36]  P. Gurbel,et al.  Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. , 2010, American heart journal.

[37]  G. Lemesle,et al.  Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. , 2010, Thrombosis research.

[38]  S. Steinhubl,et al.  Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. , 2010, Journal of the American College of Cardiology.

[39]  M. Fromm,et al.  Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. , 2010, Journal of the American College of Cardiology.

[40]  Masafumi Ueno,et al.  Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. , 2010, Journal of the American College of Cardiology.

[41]  S. Umemura,et al.  Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[42]  A. Kastrati,et al.  Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2010, Circulation.

[43]  A. Kastrati,et al.  Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement , 2010, Journal of thrombosis and haemostasis : JTH.

[44]  Osamu Okazaki,et al.  Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite , 2010, Drug Metabolism and Disposition.

[45]  P. Barragan,et al.  Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. , 2009, The American journal of cardiology.

[46]  D. Kereiakes,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[47]  Osamu Okazaki,et al.  A Possible Mechanism for the Differences in Efficiency and Variability of Active Metabolite Formation from Thienopyridine Antiplatelet Agents, Prasugrel and Clopidogrel , 2009, Drug Metabolism and Disposition.

[48]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[49]  P. Morange,et al.  Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[50]  D. Angiolillo,et al.  Clopidogrel response variability: Current status and future directions , 2009, Thrombosis and Haemostasis.

[51]  W. Ahmad.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[52]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[53]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[54]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[55]  A. Siegbahn,et al.  Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. , 2008, Journal of the American College of Cardiology.

[56]  B. Jilma,et al.  Calcium channel blockers reduce the antiplatelet effect of clopidogrel , 2008, Journal of the American College of Cardiology.

[57]  M. Vaduganathan,et al.  Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. , 2008, Journal of the American College of Cardiology.

[58]  T. Furuta,et al.  The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects , 2008, Journal of thrombosis and haemostasis : JTH.

[59]  Matthew J Price,et al.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.

[60]  S. Iturria,et al.  Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel , 2007, Journal of thrombosis and haemostasis : JTH.

[61]  R. Blindt,et al.  The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis , 2007, Thrombosis and Haemostasis.

[62]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[63]  P. Auquier,et al.  Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events , 2007, Journal of thrombosis and haemostasis : JTH.

[64]  K. Winters,et al.  Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently , 2007, Clinical pharmacology and therapeutics.

[65]  A. Bura,et al.  Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. , 2006, Blood.

[66]  G. Montalescot,et al.  A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.

[67]  P. Gurbel,et al.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.

[68]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[69]  F. Neumann,et al.  Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention , 2005, Circulation.

[70]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[71]  S. Kunapuli,et al.  Central role of the P2Y12 receptor in platelet activation. , 2004, The Journal of clinical investigation.

[72]  P. Watkins,et al.  Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.

[73]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[74]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[75]  K. Harjai,et al.  Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina? , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[76]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[77]  M. Maftouh,et al.  Structure and stereochemistry of the active metabolite of clopidogrel. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[78]  P. Järemo,et al.  Individual variations of platelet inhibition after loading doses of clopidogrel , 2002, Journal of internal medicine.

[79]  S. Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study ☆ , 2002 .

[80]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[81]  David Julius,et al.  Identification of the platelet ADP receptor targeted by antithrombotic drugs , 2001, Nature.

[82]  J. Herbert,et al.  Identification and Biological Activity of the Active Metabolite of Clopidogrel , 2000, Thrombosis and Haemostasis.

[83]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[84]  S. Werns.  Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial , 2012 .

[85]  M. Cheitlin.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2010 .

[86]  Cytochrome 2 C 19 * 17 Allelic Variant , Platelet Aggregation , Bleeding Events , and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement , 2011 .

[87]  P. Gurbel,et al.  The difference between clopidogrel responsiveness and posttreatment platelet reactivity. , 2005, Thrombosis research.

[88]  Timi Study,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation , 2005 .

[89]  P. Barragan,et al.  Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylation , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[90]  A. Kastrati,et al.  A RANDOMIZED COMPARISON OF ANTIPLATELET THERAPY AFTER THE PLACEMENT OF CORONARY ARTERY STENTS , 1996 .